Investors focused on the Retail-Wholesale space have likely heard of Haverty Furniture Companies (HVT), but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company’s year-to-date performance in comparison to the rest of the Retail-Wholesale sector should help us answer this question.
Haverty Furniture Companies is one of 213 companies in the Retail-Wholesale group. The Retail-Wholesale group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. HVT is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for HVT’s full-year earnings has moved 23.13% higher. This shows that analyst sentiment has improved and the company’s earnings outlook is stronger.
According to our latest data, HVT has moved about 28.26% on a year-to-date basis. In comparison, Retail-Wholesale companies have returned an average of -6.39%. As we can see, Haverty Furniture Companies is performing better than its sector in the calendar year.
Looking more specifically, HVT belongs to the Retail – Home Furnishings industry, which includes 9 individual stocks and currently sits at #56 in the Zacks Industry Rank. Stocks in this group have gained about 51.11% so far this year, so HVT is slightly underperforming its industry this group in terms of year-to-date returns.
Investors in the Retail-Wholesale sector will want to keep a close eye on HVT as it attempts to continue its solid performance.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.